Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.53 |
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4242083 | 0.91 | BACE1 (0.52) | BACE1DHODHKDM4EALDH1A1 | |
| SCHEMBL7716692 | 0.80 | QTRT1 (0.52) | DAODHODHABCB1 | |
| SCHEMBL8237842 | 0.79 | BACE1 (0.62) | BACE1DHFRMAOBABCB1HTR1A | |
| SCHEMBL4245709 | 0.76 | AOC3 (0.54) | BACE1DAODHFR | |
| SCHEMBL16324218 | 0.72 | NPY5R (0.60) | KDM4E | |
| Trifluoroacetic Acid SCHEMBL4245228 | 0.72 | BACE1 (0.56) | BACE1 | |
| SCHEMBL7716578 | 0.71 | PLA2G7 (0.48) | ALDH1A1 | |
| SCHEMBL17779986 | 0.71 | BACE1 (0.62) | BACE1MAOBABCB1HTR1ADRD2 | |
| SCHEMBL7712389 | 0.70 | MAPT (0.49) | KDM4EALDH1A1 | |
| SCHEMBL4941238 | 0.69 | BACE1 (1.00) | BACE1DHFRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2007058580-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | BACE1 9/4885DAO 423/4885DHFR 2514/4885 |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | BACE1 9/4885DAO 423/4885DHFR 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.